FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileALK-Abelló A/S
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AKBLF
ALK-Abelló A/S Stock AnalysisComprehensive stock analysis for ALK-Abelló A/S (AKBLF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAKBLF
AKBLF
ALK-Abelló A/S
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AKBLF
  1. Home
  2. Stocks
  3. ALK-Abelló A/S

ALK-Abelló A/S

🇺🇸AKBLF•OTC

ALK-Abelló A/S

🇺🇸AKBLF•OTC
Market cap
$7.27B
P/E ratio
37.79

Your view on AKBLF

Mkt Cap
$7.27B
P/E
37.79
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ALK-Abelló A/S

Industry
Biotechnology
Sector
Healthcare
CEO
Peter Halling
Headquarters
Boge Alle 6-8, Horsholm, DK
Industry
Biotechnology
Sector
Healthcare
CEO
Peter Halling
Headquarters
Boge Alle 6-8, Horsholm, DK
Description

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar.

It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma.

ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for ALK-Abelló A/S from FRC's valuation model, read against the market price. AKBLF last traded at $36.10, 37.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for ALK-Abelló A/S. Starting points for ALK-Abelló A/S: P/E 37.8, EPS $6.33, beta 0.58 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for ALK-Abelló A/S. ALK-Abelló A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for ALK-Abelló A/S. Trailing twelve-month EPS for ALK-Abelló A/S stands at $6.33. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for ALK-Abelló A/S. ALK-Abelló A/S has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AKBLF12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
MSLESatellos Bioscience Inc.HealthcareNASDAQ$7.3M
MSRMMushrooms IncHealthcareOTC$233,727
MTNBMatinas BioPharma Holdings, Inc.HealthcareAMEX$341,620
MTVAMetaVia Inc.HealthcareNASDAQ$6.8M
MXCTMaxCyte, Inc.HealthcareNASDAQ$141.5M
MYMXMymetics CorporationHealthcareOTC$46
MYNDFMYND Life Sciences Inc.HealthcareOTC$657,843
NAGENiagen Bioscience IncHealthcareNASDAQ$145.7M
NAMSNewAmsterdam Pharma Company N.V.HealthcareNASDAQ$2.2B
NAMSWNewAmsterdam Pharma Company N.V.HealthcareNASDAQ$1.8B
NAUTNautilus Biotechnology, Inc.HealthcareNASDAQ$270.0M
NAVBQNavidea Biopharmaceuticals, Inc.HealthcareOTC$100
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for ALK-Abelló A/S. Coverage tracks ALK-Abelló A/S within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of ALK-Abelló A/S.

AKBLF AnalysisGood
Past
2
Growth
4
Health
5
Profit
3
Value
1